Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - idarubicin hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - idarubicin hydrochloride 10mg; idarubicin hydrochloride 10mg; idarubicin hydrochloride 10mg - capsule - 10 mg - active: idarubicin hydrochloride 10mg excipient: gelatin glyceryl palmito-stearate iron oxide red microcrystalline cellulose opacode black s-1-27794 titanium dioxide active: idarubicin hydrochloride 10mg excipient: gelatin glyceryl palmito-stearate iron oxide red microcrystalline cellulose titanium dioxide active: idarubicin hydrochloride 10mg excipient: gelatin glyceryl palmito-stearate iron oxide red microcrystalline cellulose tekprint black sw-9008 titanium dioxide - zavedos is an antimitotic and cytotoxic agent. it is indicated for use in acute myelogenous leukaemia (aml), in adults for remission induction in untreated patients, or for remission induction in relapsed or refractory patients. zavedos capsules are indicated whenever the intravenous route is not considered suitable. zavedos is also an effective agent for use in the second line treatment of advanced breast cancer either as a single agent or in a combination regimen.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - idarubicin hydrochloride 25mg; idarubicin hydrochloride 25mg; idarubicin hydrochloride 25mg - capsule - 25 mg - active: idarubicin hydrochloride 25mg excipient: gelatin glyceryl palmito-stearate microcrystalline cellulose opacode black s-1-27794 titanium dioxide active: idarubicin hydrochloride 25mg excipient: gelatin glyceryl palmito-stearate microcrystalline cellulose titanium dioxide active: idarubicin hydrochloride 25mg excipient: gelatin glyceryl palmito-stearate microcrystalline cellulose tekprint black sw-9008 titanium dioxide - zavedos is an antimitotic and cytotoxic agent. it is indicated for use in acute myelogenous leukaemia (aml), in adults for remission induction in untreated patients, or for remission induction in relapsed or refractory patients. zavedos capsules are indicated whenever the intravenous route is not considered suitable. zavedos is also an effective agent for use in the second line treatment of advanced breast cancer either as a single agent or in a combination regimen.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - idarubicin hydrochloride 5mg; idarubicin hydrochloride 5mg; idarubicin hydrochloride 5mg - capsule - 5 mg - active: idarubicin hydrochloride 5mg excipient: gelatin glyceryl palmito-stearate iron oxide red microcrystalline cellulose opacode black s-1-27794 titanium dioxide active: idarubicin hydrochloride 5mg excipient: gelatin glyceryl palmito-stearate iron oxide red microcrystalline cellulose titanium dioxide active: idarubicin hydrochloride 5mg excipient: gelatin glyceryl palmito-stearate iron oxide red microcrystalline cellulose tekprint black sw-9008 titanium dioxide - zavedos is an antimitotic and cytotoxic agent. it is indicated for use in acute myelogenous leukaemia (aml), in adults for remission induction in untreated patients, or for remission induction in relapsed or refractory patients. zavedos capsules are indicated whenever the intravenous route is not considered suitable. zavedos is also an effective agent for use in the second line treatment of advanced breast cancer either as a single agent or in a combination regimen.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - idarubicin hydrochloride 10mg - powder for injection - 10 mg - active: idarubicin hydrochloride 10mg excipient: lactose monohydrate - latest regulatory activity

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - idarubicin hydrochloride 20mg - powder for injection - 20 mg - active: idarubicin hydrochloride 20mg excipient: lactose monohydrate

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - idarubicin hydrochloride 5mg - powder for injection - 5 mg - active: idarubicin hydrochloride 5mg excipient: lactose monohydrate

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - idarubicin hydrochloride - solution for injection - 1 milligram(s)/millilitre - anthracyclines and related substances; idarubicin

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - idarubicin hydrochloride - capsule, hard - 10 milligram(s) - anthracyclines and related substances; idarubicin

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - idarubicin hydrochloride - capsule, hard - 5 milligram(s) - anthracyclines and related substances; idarubicin